skip to primary navigationskip to content
 

Life sciences equity crowdfunding platform, Capital Cell shortlisted for international award

last modified Jun 23, 2017 03:38 PM
Shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017

Today, ideaSpace West members, Capital Cell, Europe’s first equity crowdfunding platform specialised in life science, has been shortlisted for the prestigious Best International Growth Business award at the UK Business Angels Association Investment Awards 2017.

Capital Cell has been trading in Spain for just over 2 years, and has successfully closed 14 life science crowdfunding campaigns, including the country’s largest life science crowdfunding campaign of over 1.2M, for a potential therapeutic cure for MS.

Scaling-up from this Spanish platform, Capital Cell UK has just launched at www.capitalcell.co.uk, with a range of companies solving unmet needs from malaria control to female fertility enhancement and autoimmune disease.

In recognition of their contribution to the European life science ecosystem, the company has now been shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017.

‘We are absolutely thrilled that Capital Cell has been recognised so early on in it’s expansion into the UK,’ says Laura Ferguson, UK Director. ‘The reception to our arrival has been overwhelmingly positive from players throughout the life science ecosystem, including specialised investors such as Angels in MedCity, with whom we are collaborating closely, as well as the NHS innovation, science parks and startup incubators. It’s wonderful to have that traction formally recognised’.

The UKBAA black-tie awards dinner will take place on July the 6th, at the Dorchester Hotel, London, with 300 leading innovators and investors assembled to celebrate the best of UK business.page1image17296page1image17456page1image17616

Capital Cell has already proven itself as a platform for early stage investment in a very challenging environment’, Chairman Ian Tomlinson adds, ‘so we are extremely excited about scaling up in the UK, which is a global leader not only in life science innovation but also in equity crowdfunding. As an investment area, life science has the potential for both huge social impact and significant financial returns and the companies listed on Capital Cell are all trying to solve a major unmet medical need. By opening up these investment opportunities to more people we hope to be able to help the UK remain at the cutting edge of life science commercialisation.'

About Capital Cell: 

Capital Cell was founded by Daniel Oliver, CEO, and has been trading in Spain for just over 2 years from their main operational office in Barcelona. Following investment into Capital Cell of more than 500k, including UK and Spanish business angels as well as “crowd” investment from their own 300kcrowdfunding campaign closed in March 2017, the company has now launched in the UK. Daniel Oliver remains in majority control of the company, with the UK launch being led alongside Laura Ferguson, UK Director.

Ian Tomlinson, UK Chairman (www.stevenagecatalyst.com/about/board_directors/ian_tomlinson/) was the co-founder of Domantis Ltd which was acquired by GSK for $454 million in 2006, and is also current Chairman of Stevenage BioScience Catalyst.

For more information, please contact:

Katie Anderton

Head of Marketing and Capital Cell

katie@capitalcell.net 

RSS Feed Latest news

Celebrating World Environment Day - Polysolar’s Contribution to Saving our Planet

Jun 05, 2019

ideaSpace exists to support founders with scalable innovative ideas which could potentially address global threats like climate change. To celebrate World Environment Day we spoke to Hamish Watson, founder of ideaSpace alumni company Polysolar – a leader in the provision of solar PV glass for energy generation in buildings. He took us through Polysolar’s story, from product inception to where it is today, and shared his thoughts on the secret to the company’s success, the challenges that have shaped its growth, and some advice on crowdfunding.

LESSONS FOR A FOUNDER - 10 Things a Start-up Company Should Consider When Writing a Communications Plan

May 29, 2019

Lorna Cuddon set up Zyme Communications 10 years ago to focus on early stage life science companies as she saw a gap in the market for a Cambridge based company. At our recent B3 event Lorna shared what an early stage start-up needs to consider in their communications. She first touched on why you need it. Communications is essential to support corporate objectives; whether its raising investment or creating commercial leads and sales revenue, establishing partnerships or raising the company profile to support a recruitment drive – the comms plan can help! We took the top 10 tips from Lorna’s talk – read on to find out what you can do to up your communications game.

View all news